MS drug developer Kyverna Therapeutics files for $100 million IPO
Chunumunu Kyverna Therapeutics (KYTX), which is developing therapies for autoimmune disorders such as lupus and multiple sclerosis, has filed a ...
Chunumunu Kyverna Therapeutics (KYTX), which is developing therapies for autoimmune disorders such as lupus and multiple sclerosis, has filed a ...